hepatitis E virus infection

Summary

hepatitis E virus infection (MONDO:0005788) is a disease and 5 clinical trials. Top therapeutic interventions include ursodiol. A subtype of viral hepatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hepatitis E virus infection
Mondo ID	MONDO:0005788
EFO	EFO:0007303
MeSH	D016751
DOID	DOID:4411
SNOMED CT	7111000119109
UMLS	C0085293
MedGen	88376
Is cancer (heuristic)	no

Also known as: Hepatitis E virus caused hepatitis · Hepatitis E virus hepatitis · hepatitis type E

Disease family

This is a subtype of viral hepatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › hepatitis › viral hepatitis › hepatitis E virus infection

Related subtypes (5): Epstein-Barr virus hepatitis, hepatitis C virus infection, hepatitis B virus infection, hepatitis D virus infection, hepatitis A virus infection

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

3 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Hepatitis B Virus Hbsag Surface Protein Antigen	Phase 3
Silybin A	Phase 2
Sodium Chloride	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05415345	PHASE4	UNKNOWN	Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin
NCT06306196	PHASE2	RECRUITING	Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
NCT07525401	Not specified	NOT_YET_RECRUITING	Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis
NCT02645955	Not specified	COMPLETED	Epidemiological Study of Hepatitis E Virus in Maintenance Hemodialysis Patients
NCT05300425	Not specified	COMPLETED	Seroprevalence of Leptospirosis in Val Müstair, Switzerland

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
URSODIOL	4	2
CHEMBL5409583	0	1